|
시장보고서
상품코드
2078410
신경인성 배뇨근 과활동 시장 규모, 점유율 및 성장 분석 : 치료법별, 원인별, 유통경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Neurogenic Detrusor Overactivity Market Size, Share, and Growth Analysis, By Treatment (Anticholinergics (Oxybutynin, Tolterodine)), By Cause (Spinal Cord Injury, Multiple Sclerosis), By Distribution, By End-User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 신경인성 배뇨근 과활동 시장 규모는 2024년에 6억 8,250만 달러로 평가되었고, 2025년 7억 2,563만 달러에서 2033년까지 11억 8,540만 달러로 성장하여 예측 기간(2026-2033년)에 CAGR 6.32%를 기록할 전망입니다.
신경성 배뇨근 과활동 세계 시장에는 척수 손상, 다발성 경화증, 파킨슨병 등의 질환에 따른 비자발적 방광 수축을 치료하기 위해 고안된 의약품, 의료기기 및 디지털 치료법이 포함됩니다. 이 시장은 환자의 삶의 질을 향상시키고, 요로 감염이나 신장 문제와 같은 고비용 합병증을 줄이는 데 있어 매우 중요합니다. 이 시장의 성장은 인구 동향의 변화와 신경계 질환 진단 건수 증가에 따른 환자 수 증가에 힘입어 이루어지고 있습니다. 평균 수명이 늘어남에 따라 혁신적인 치료법에 대한 수요가 높아지고 있습니다. 각 기업은 보툴리눔툭신(보톡스) 제제와 충전식 자극 장치의 개발을 우선시하고 있으며, 경구용 약물에 비해 신경 자극 장치 사용 후 병원 입원 건수가 현저히 감소하고 있다는 점이 보험사 등으로 하여금 이러한 대체 요법을 지지하도록 설득하고 있어, 방광 모니터링 솔루션에 주력하는 스타트업 기업들에게 비즈니스 기회를 창출하고 있습니다.
세계 신경인성 배뇨근 과활동 시장의 성장 요인
척수 손상, 다발성 경화증, 파킨슨병 및 기타 신경성 질환의 유병률 증가로 인해 효과적인 방광 관리 솔루션에 대한 수요가 크게 증가하고 있습니다. 이러한 수요의 급증으로 인해, 의료 종사자들은 신경인성 배뇨근 과활동증의 치료법을 표준 치료 프로토콜에 포함시키고 있습니다. 그 결과, 처방률이 현저히 상승하고 있을 뿐만 아니라, 혁신적인 투여 시스템의 도입과 제품 개발에 대한 투자 확대도 진행되고 있습니다. 이러한 시너지 효과 덕분에 전 세계의 병원, 전문 클리닉, 지역 의료 현장에서 시장 입지가 확대되고 있습니다. 그 결과, 이러한 요인들이 세계 시장의 이해관계자들에게 지속 가능한 성장과 탄탄한 비즈니스 기회의 기반을 마련해 주고 있습니다.
세계 신경인성 배뇨근 과활동 시장의 제약 요인
신경인성 배뇨근 과활동증에 대한 첨단 의약품 및 이식형 의료기기로 인한 높은 비용은 환자, 보험사, 의료 서비스 제공업체에게 큰 경제적 과제가 되고 있습니다. 이로 인해 환자와 의료 서비스 제공업체들이 효과는 떨어지지만 가격이 더 저렴한 대안을 선택하는 경우가 늘어나면서, 처방률이 감소하는 추세를 보이고 있습니다. 또한, 보험 환급과 관련된 불확실성이나 보험 적용 방침의 불일치가, 특히 예산 제약이 치료 방침에 큰 영향을 미치는 지역에서 치료법의 활용을 저해하고 있습니다. 이러한 상황은 시장의 성장을 저해할 뿐만 아니라, 개발 기업들의 투자 매력을 떨어뜨려, 결국 이 분야의 혁신적인 차세대 치료법의 발전과 시장 출시를 지연시키는 결과로 이어집니다.
세계 신경인성 배뇨근 과활동 시장 동향
세계 신경인성 배뇨근 과활동성 시장에서는 맞춤형 신경 조절 요법의 도입을 향한 뚜렷한 추세가 나타나고 있습니다. 영상 진단 기술과 인공지능의 발전으로 인해, 임상의가 개별 환자의 필요에 맞추어 치료 계획을 맞춤 설정할 수 있는 플랫폼이 등장하고 있습니다. 이러한 환자 중심의 접근 방식은 치료 효과를 높이고, 부작용을 최소화하며, 환자의 만족도를 현저히 향상시킵니다. 이전에는 표준화된 치료법 도입에 소극적이었던 비뇨기과 의사들도 현재는 이러한 혁신적인 해결책을 채택하는 경향이 강해지고 있습니다. 그 결과, 적응성이 높은 의료기기 및 동반 진단 서비스에 대한 수요가 급증하고 있으며, 이는 전 세계 의료 시스템에서 가치 기반 보상 모델로의 광범위한 전환과 맞물려 진행되고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 신경인성 배뇨근 과활동 시장 규모 : 치료별
세계의 신경인성 배뇨근 과활동 시장 규모 : 원인별
세계의 신경인성 배뇨근 과활동 시장 규모 : 유통별
세계의 신경인성 배뇨근 과활동 시장 규모 : 최종사용자별
세계의 신경인성 배뇨근 과활동 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
LSH 26.07.08Global Neurogenic Detrusor Overactivity Market size was valued at USD 682.5 Million in 2024 and is poised to grow from USD 725.63 Million in 2025 to USD 1185.4 Million by 2033, growing at a CAGR of 6.32% during the forecast period (2026-2033).
The global market for neurogenic detrusor overactivity includes pharmaceutical treatments, medical devices, and digital therapies designed to address involuntary bladder contractions associated with conditions like spinal cord injuries, multiple sclerosis, and Parkinson's disease. This market is crucial for enhancing patient quality of life and mitigating expensive complications such as urinary tract infections and renal issues. Growth is driven by an increasing patient population resulting from demographic shifts and more frequent diagnoses of neurological conditions. As life expectancy rises, there is a heightened demand for innovative therapies. Companies are prioritizing advancements in botulinum toxin formulations and rechargeable stimulators, while a notable decrease in hospital admissions following the use of neurostimulators over oral medications is convincing payers to support these alternatives, fostering opportunities for startups that focus on bladder monitoring solutions.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neurogenic Detrusor Overactivity market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Neurogenic Detrusor Overactivity Market Segments Analysis
Global neurogenic detrusor overactivity market is segmented by treatment, cause, distribution, end-user and region. Based on treatment, the market is segmented into Anticholinergics (Oxybutynin, Tolterodine), Beta-3 Agonists (Mirabegron), Botulinum Toxin Injections and Sacral Neuromodulation. Based on cause, the market is segmented into Spinal Cord Injury, Multiple Sclerosis and Parkinson's Disease. Based on distribution, the market is segmented into Hospital Pharmacies and Specialty Pharmacies. Based on end-user, the market is segmented into Urology Clinics and Neurology Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Neurogenic Detrusor Overactivity Market
The increasing prevalence of spinal cord injuries, multiple sclerosis, Parkinson's disease, and other neurogenic disorders is significantly driving the demand for effective bladder management solutions. This surge prompts healthcare professionals to incorporate neurogenic detrusor overactivity therapies into standard treatment protocols. As a result, there is a notable rise in prescription rates, alongside the integration of innovative delivery systems and enhanced investment in product development. This combined effect is broadening market presence in hospitals, specialty clinics, and community health settings worldwide. Consequently, these factors are establishing a foundation for sustained growth and robust opportunities for stakeholders in the global market.
Restraints in the Global Neurogenic Detrusor Overactivity Market
The high costs associated with advanced pharmaceuticals and implantable devices for neurogenic detrusor overactivity create a considerable financial challenge for patients, insurers, and healthcare providers. This often leads to a reduction in prescription rates as both patients and providers may opt for more affordable, albeit less effective, alternatives. Additionally, uncertainties regarding reimbursement and inconsistent coverage policies hinder utilization, particularly in regions where budget constraints heavily influence treatment decisions. This environment not only restricts the market's growth but also diminishes investment appeal for developers, ultimately delaying the advancement and release of innovative, next-generation therapies in the field.
Market Trends of the Global Neurogenic Detrusor Overactivity Market
The Global Neurogenic Detrusor Overactivity market is experiencing a significant trend towards the adoption of personalized neuromodulation therapies. As a result of advancements in imaging technology and artificial intelligence, platforms are emerging that enable clinicians to customize treatment settings tailored to individual patient needs. This patient-centric approach enhances therapeutic outcomes, minimizes side effects, and notably increases patient satisfaction levels. Urologists, previously reluctant to embrace standardized treatments, are now more inclined to adopt these innovative solutions. Consequently, there is a burgeoning demand for adaptable devices and companion diagnostic services, coinciding with a broader shift towards value-based reimbursement models in healthcare systems worldwide.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Neurogenic Detrusor Overactivity Market Size by Treatment & CAGR (2026-2033)
- Market Overview
- Anticholinergics (Oxybutynin, Tolterodine)
- Beta-3 Agonists (Mirabegron)
- Botulinum Toxin Injections
- Sacral Neuromodulation
Global Neurogenic Detrusor Overactivity Market Size by Cause & CAGR (2026-2033)
- Market Overview
- Spinal Cord Injury
- Multiple Sclerosis
- Parkinson's Disease
Global Neurogenic Detrusor Overactivity Market Size by Distribution & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Specialty Pharmacies
Global Neurogenic Detrusor Overactivity Market Size by End-User & CAGR (2026-2033)
- Market Overview
- Urology Clinics
- Neurology Clinics
Global Neurogenic Detrusor Overactivity Market Size & CAGR (2026-2033)
- North America (Treatment, Cause, Distribution, End-User)
- US
- Canada
- Europe (Treatment, Cause, Distribution, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Treatment, Cause, Distribution, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Treatment, Cause, Distribution, End-User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Treatment, Cause, Distribution, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Allergan (AbbVie) - Botox
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Astellas Pharma (Myrbetriq)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Medtronic plc (InterStim)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Axonics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Laborie Medical Technologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Coloplast A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Watson Pharmaceuticals (Allergan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Indivior plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Urovant Sciences (Sumitomo)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Theravance Biopharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Velicept Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- UroGen Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Taris Biomedical (Allergan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ironwood Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cogentix Medical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Stratasys Medical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cesca Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Akron Biotech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
